Kolistimetatnatrium Noridem Noridem Enterprises (Colistimethate Sodium)

Colistimethate sodium binds to lipopolysaccharides on the outer membrane of Gram‑negative bacteria, disrupting membrane integrity. This increased permeability leads to leakage of cellular contents and bacterial cell death, effectively clearing airway infections.

The specific dose and dosing schedule of Kolistimetatnatrium Noridem are determined by the prescribing clinician based on the patient’s age, weight, severity of infection, and renal function. The prescriber will set the appropriate regimen.

The safety of colistimethate sodium in pregnancy and lactation has not been established. Clinicians should consider the potential benefits against possible risks and may opt for alternative therapies when safer options are available.

To request Kolistimetatnatrium Noridem, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Colistimethate sodium is a polymyxin antibiotic specifically formulated for inhalation, delivering high local concentrations in the lungs with limited systemic exposure. Compared with intravenous antibiotics, it offers targeted therapy for chronic Pseudomonas infections in cystic fibrosis, often with fewer systemic side effects.

Store the inhalation solution at room temperature, below 25 °C, in its original container. Protect it from light, moisture and extreme temperatures. Do not freeze the product, and keep the vial tightly sealed when not in use.

Kolistimetatnatrium Noridem is administered via a nebulizer. The prescribed dose is added to the nebulizer cup, and the patient inhales the aerosolized solution according to the clinician’s instructions, typically once or twice daily.

Serious risks include bronchial hemorrhage, severe allergic reactions such as anaphylaxis, acute renal toxicity, neuromuscular blockade leading to muscle weakness, and rare neurotoxic events like seizures. Patients should be monitored closely for these events.

Colistimethate sodium should be avoided in patients with known hypersensitivity to polymyxins, those with severe renal impairment without dose adjustment, individuals with myasthenia gravis or other neuromuscular disorders, and patients experiencing active bronchospasm unless under medical supervision.